Introduction Clinical course of membranous nephropathy (MN) is difficult to predict.
Measurement of circulating anti-PLA2R autoantibodies (PLA2R-Ab) and detection in …

The discovery of anti-podocyte antibodies in primary membranous nephropathy (MN) has
revolutionized our approach toward the diagnosis and treatment of this disease. Evaluation …

Complement activation has long been recognized as a central feature of membranous
nephropathy. Evidence for its role has been derived from the detection of complement …

The diagnostic performance of M-type phospholipase A2 receptor (PLA2R) autoantibodies
and PLA2R glomerular staining in discriminating between idiopathic membranous …

Rituximab offers an alternative to current immunosuppressive therapies for difficult-to-treat
nephrotic syndrome. The best outcomes are seen in patients with steroid-dependent …

Abstract Background HP Acthar® Gel is currently the only Food and Drug Administration
therapy approved for the treatment of nephrotic syndrome. Active drug ingredients include …

The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
represents the first update to this set of recommendations since the initial set of KDIGO …

Membranous glomerulonephritis (MGN) is a common cause of nephrotic syndrome in adults,
mediated by glomerular antibody deposition to an increasing number of newly recognised …

Exciting progress recently has been made in our understanding of idiopathic membranous
nephropathy, as well as treatment of this disease. Here, we review important advances …

Background Idiopathic membranous nephropathy (MN) is a common immune-mediated
glomerular disease and the main cause of nephrotic syndrome (NS) in Caucasian adults …